Physician profile
John C King
NPI 1285674119
$730.77
in general payments reported to CMS, 2019-2025
9 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.79 · 2020: $30.79 · 2022: $97.38 · 2023: $33.75 · 2024: $149 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $277.47 | 2023-2025 | Nucala, Trelegy Ellipta |
| Tactile Systems Technology INC | $91.62 | 2022-2024 | Flexitouch Plus, Entre Plus |
| Philips North America LLC | $88.05 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Astrazeneca Pharmaceuticals Lp | $73.41 | 2019-2025 | Breztri |
| Genzyme Corporation | $53.74 | 2025 | |
| Sanofi-Aventis U.S. LLC | $45.66 | 2019 | |
| Insmed, INC. | $41.86 | 2025 | Brinsupri, Arikayce |
| Regeneron Healthcare Solutions, INC. | $41.11 | 2025 | Dupixent |
| Genentech USA, INC. | $17.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.